Document:

EXHIBIT 10.2

  

  

    

    AMENDMENT 1 TO EMPLOYMENT AGREEMENT

    

    

    THIS AMENDMENT 1 TO EMPLOYMENT AGREEMENT (this “Amendment 1”) is made and entered into as of August 2, 2022, by and between Affinity Bancshares, Inc., a Maryland Corporation (the “Corporation”), Affinity Bank, a federally-chartered savings association organized under the laws of the United States of America (the “Bank”) and Brandi Pajot (the “Executive”).

    

    

    RECITALS:

    

    

    WHEREAS, the Bank, the Company and
        the Executive entered into that certain Employment Agreement, dated as of May 24, 2021 (the “Employment Agreement”) providing
        for an initial term of one year, which Employment Agreement was renewed for an additional year, so that the current term of the Employment Agreement expires on September 1, 2022;

    

    

    WHEREAS, the Company and the Bank have appointed the Executive to the executive position of Chief Financial Officer effective as of July
      28, 2022;

    

    

    WHEREAS, the parties to the Employment Agreement wish to amend the Employment Agreement to reflect the change in the Executive’s
      position Chief Financial Officer and to increase the term of the agreement to two years with corresponding potential severance payments.

    

    

    NOW THEREFORE, effective as of August 2, 2022, and in
        consideration of the foregoing and for other good and valuable consideration, the receipt, adequacy, and sufficiency of which are hereby acknowledged, the
      Bank, the Company and the Executive hereby agree as follows:

    

    

    
      	
              1.

            	
              Definitions.

            

    

    

    

    Section 1.11(b), “Good Reason,” is deleted in its entirety and replaced with the following new Section 1.11(b):

    

    

    “(b) the failure of the Board of Directors to maintain the Executive’s appointment to the office of Chief Financial Officer of the Employer; or”

    

    

    
      	
              2.

            	
              Duties.

            

    

    

    

    The first sentence of Section 2.1 is deleted in its entirety and replaced with the following new sentence, with the remaining language of
      Section 2.1 remaining unchanged:

    

    

    “The Executive is employed as Chief Financial Officer of the Employer, subject to the direction of the Board of Directors or its designee(s).”

    

    

    
      	
              3.

            	
              Term and Termination.

            

    

    

    

    Section 3.3.1 is deleted in its entirety and replaced with the following new Section 3.3.1:

    

    

    

    

    “3.1.1. Term and Annual Renewal.  The initial term of this Agreement shall begin as of the Effective Date and shall continue for twenty-four (24) months.  Commencing on September 1,
        2022 (the “Renewal Date”) and continuing on each Renewal Date thereafter, the term of this Agreement shall renew so that the remaining term of this Agreement is twenty-four (24) months; provided, however, that the disinterested members of the
        Boards of Directors must take the

    
      
        

    

    

    

    following actions within the time frames set forth below prior to each Renewal Date: (1) at least 30 days prior to each Renewal Date,
      conduct or review a comprehensive performance evaluation of the Executive for purposes of determining whether to extend this Agreement; and (2) affirmatively approve the renewal or non-renewal of this Agreement, which decision shall be included in
      the minutes of the meeting of the Board of Directors.  If the decision of the disinterested members of the Board of Directors is not to renew this Agreement, then the Board of Directors shall provide the Executive with a written notice of non-renewal
      (the “Non-Renewal Notice”) prior to any Renewal Date, and the term of this Agreement shall terminate at the end of the then remaining term.  Reference herein
      to the term of this Agreement shall refer to both the initial term and any extended terms.”

    

    

    Section 3.3.2 is deleted in its entirety and replaced with the following new Section 3.3.2:

    

    

    “3.1.2 Change in Control.  Notwithstanding the foregoing, in the event the Bank or the Company has entered into an agreement to effect a transaction that would be considered a Change
        in Control, the term of this Agreement shall be extended automatically so that it is scheduled to expire no less than two (2) years beyond the effective date of the Change in Control, subject to extensions as set forth above.”

    

    

    
      	
              4.

            	
              Compensation.

            

    

    

    

    The first paragraph of Section 4.8 is deleted in its entirety and replaced with the following new Section 4.8:

    

    

    “4.8 Change in Control. In the event of the Executive’s termination of employment without Cause or with Good Reason during the term upon or following a Change in
        Control, the  Employer (or its successor) shall pay to the Executive an amount equal to the product of two (2) multiplied by the Executive’s average annual Base Salary, bonus and profit sharing paid by the Employer to the Executive, (the “Benefit”) as measured over the preceding three full fiscal years prior to the Change in Control (or the average annualized Base
        Salary and bonus paid to the Executive for such shorter period as the Executive has been employed by the Employer), but not less than her current Base Salary annualized plus bonus and profit sharing paid to the Executive in the prior calendar year
        immediately preceding such Change in Control. The Benefit shall be paid in cash in a lump sum within five (5) days following the effective date of the Executive’s termination of employment. The Employer shall be entitled to withhold appropriate
        employment and income taxes, if required by applicable law, should the Benefit become payable.”

    

    

    

    

    [Signature Page Follows]

    
      
        

    

    

    

    IN WITNESS WHEREOF, the parties hereto have hereunto
        executed this Agreement in accordance with the provisions hereof.

    

    

    Executed this 2nd day of August 2022.

    

    

    /s/ Brandi Pajot 

    BRANDI PAJOT

    

    

    Executed this 2nd day of August 2022.

    

    

    /s/ Edward J. Cooney 

    AFFINITY BANCSHARES, INC.

    

    

    By: Edward J. Cooney

    Title: Chief Executive Officer

    

    

    Executed this 2nd day of August 2022.

    

    

    /s/ Edward J. Cooney 

    AFFINITY BANK

    

    

    By: Edward J. Cooney

    Title: Chief Executive OfficerDocument

Exhibit 10.1

AMENDMENT NO. 5 TO PHARMACY MASTER SERVICES AGREEMENT
THIS AMENDMENT NO. 5 (this “Amendment”) to the Agreement (as defined below) is entered into as of June 24, 2022 (the “Amendment Effective Date”) by and between Jazz Pharmaceuticals, Inc. with a principal place of business at 3170 Porter Drive, Palo Alto, CA 94304 (“Jazz Pharmaceuticals”) and Express Scripts Specialty Distribution Services, Inc. with a principal place of business at One Express Way, St. Louis, MO 63121 (“ESSDS”) (collectively, the “Parties,” or each separately, a “Party”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.

RECITALS

WHEREAS, Jazz Pharmaceuticals and ESSDS entered into that certain Pharmacy Master Services Agreement (the “Agreement”), dated July 1, 2020, pursuant to which ESSDS provides dispensing, distribution and other services for Products; and

NOW THEREFORE, in consideration of the above recitals, each of which is incorporated by this reference, the mutual promises and covenants set forth below, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1.Section 11.1 Term; Renewal is deleted in its entirety and replaced with the following: Term; Renewal. Unless otherwise terminated in accordance with the terms hereof, this Agreement will remain in effect until August 31, 2022.

2.General. This Amendment constitutes an amendment in writing to the Agreement in accordance with Section 14.1 of the Agreement.

3.Governing Law. This Amendment, and any dispute related hereto, will be governed and construed in accordance with the laws of the State of Delaware, excluding any choice of law rules which may direct the application of the laws of another jurisdiction. In the event of any dispute between the Parties, prior to any Party commencing an action for damages, each Party will designate a representative and the representatives will meet in person or telephonically in a good-faith attempt to resolve their differences. Prior to such meeting, the complaining Party will provide a written explanation of the dispute.

4.Full Force and Effect. In the event of any conflict or inconsistency between the terms and provisions of the Agreement and the terms and provisions of this Amendment, the terms and provisions of this Amendment will govern and prevail. Except as expressly provided in this Amendment, this Amendment does not in any way change, modify or delete the provisions of the Agreement (or the Parties’ rights, remedies or obligations thereunder), and all such provisions shall remain in full force and effect. On and after the Amendment Effective Date, each reference in the Agreement to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of like import, and each reference to the Agreement in any other agreements, documents or instruments executed and delivered pursuant to the Agreement, shall mean and be a reference to the Agreement, as amended by this Amendment.

5.Counterparts. This Amendment may be executed in counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument. Facsimile and pdf signatures will be considered original signatures.

[Signature Page Follows]

2

IN WITNESS WHEREOF, the undersigned have caused this Amendment to be executed, effective as of the Amendment Effective Date.

						
	JAZZ PHARMACEUTICALS, INC.	EXPRESS SCRIPTS SPECIALTY
		DISTRIBUTION SERVICES, INC.
		
	By:     /s/ Ernie Ross    
	By:        /s/ Joshua B. Parker    

	Name:      Ernie Ross
	    Name:    Joshua B. Parker

	Title:         Senior VP, U.S. Market Access
	    Title:      VP

	                 29-Jun-2022
	               06/23/2022 | 9:40 AM CDT

		
		
	By:                                       
	RPM for JLD 6.23.22
	Name:
	
	Title:
	

[Signature Page to Amendment No.2 to Pharmacy Master Services Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]